These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum soluble ICAM-1 levels in the patients with cervical cancer.
    Author: Okamoto Y, Tsurunaga T, Ueki M.
    Journal: Acta Obstet Gynecol Scand; 1999 Jan; 78(1):60-5. PubMed ID: 9926894.
    Abstract:
    BACKGROUND: We hypothesize that serum levels of the soluble intercellular adhesion molecule-1 (s-ICAM-1) in patients with cervical cancer are significantly higher than that in healthy donors and this is examined in vivo, and in vitro. METHODS: We measured the serum levels of the s-ICAM-1 in patients with cervical cancer. Furthermore, in vitro, we examined the relationship between the expression of ICAM-1 on the cell surface of cultured cervical cancer cells and the s-ICAM-1 levels in the spent media. RESULTS: The mean+/-s.d. in the patients with cervical cancer 884.4+/-332.4 ng/ml were significantly (all, p<0.001) higher than those of normal controls (mean 364.6+/-134.8 ng/ml) and in patients with benign disease (536.3+/-204.8 ng/ml). Interferon-gamma (IFN-gamma) treated cells expressed more ICAM-1 on cell surfaces than did the non-treated cells, and s-ICAM-1 shed in the spent media from IFN-gamma treated cells were much higher than those of non-treated cells. CONCLUSIONS: These results indicate that the reason for increase of s-ICAM-1 in the patients with cervical cancer were both expression and shedding of ICAM-1 from cervical cancer cells especially influenced by cytokines, for example, IFN-gamma from surrounding lymphocytes.
    [Abstract] [Full Text] [Related] [New Search]